TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:34
Cabaletta Bio Inc. ( CABA ) https://www.cabalettabio.com
2.49USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-89.33%
CABA
SPY
32.66%
-36.96%
CABA
SPY
108.59%
-81.98%
CABA
SPY
302.52%
CABA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
117.74
-50.05
1.13
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.13
29.36
0.68
-39.67
0.00
0.41
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-699.03
-9.80
-765.18
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
13.2624
-86.95
-72.09
2.43
Other Earnings and Cash Flow Stats:
Cabaletta Bio Inc. ( CABA ) Net Income TTM ($MM) is -104.16
Cabaletta Bio Inc. ( CABA ) Operating Income TTM ($MM) is -114.50
Cabaletta Bio Inc. ( CABA ) Owners' Earnings Annual ($MM) is 0.00
Cabaletta Bio Inc. ( CABA ) Current Price to Owners' Earnings ratio is 0.00
Cabaletta Bio Inc. ( CABA ) EBITDA TTM ($MM) is -112.92
Cabaletta Bio Inc. ( CABA ) EBITDA Margin is -765.18%
Capital Allocation:
Cabaletta Bio Inc. ( CABA ) has paid 0.00 dividends per share and bought back -5.508526 million shares in the past 12 months
Cabaletta Bio Inc. ( CABA ) has increased its debt by 10.954 million USD in the last 12 months
Capital Structure:
Cabaletta Bio Inc. ( CABA ) Interest-bearing Debt ($MM) as of last quarter is 15
Cabaletta Bio Inc. ( CABA ) Annual Working Capital Investments ($MM) are -1
Cabaletta Bio Inc. ( CABA ) Book Value ($MM) as of last quarter is 174
Cabaletta Bio Inc. ( CABA ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
Cabaletta Bio Inc. ( CABA ) has 170 million in cash on hand as of last quarter
Cabaletta Bio Inc. ( CABA ) has 22 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Cabaletta Bio Inc. ( CABA ) has 49 common shares outstanding as of last quarter
Cabaletta Bio Inc. ( CABA ) has 0 million USD of preferred stock value
Academic Scores:
Cabaletta Bio Inc. ( CABA ) Altman Z-Score is -0.80 as of last quarter
Cabaletta Bio Inc. ( CABA ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Cabaletta Bio Inc. ( CABA ) largest shareholder is owning shares at 0.00 ($MM) value
Gwendolyn Binder(an insider) Sold 11000 shares of Cabaletta Bio Inc. ( CABA ) for the amount of $215490.00 on 2024-01-19
3.10% of Cabaletta Bio Inc. ( CABA ) is held by insiders, and 100.47% is held by institutions
Cabaletta Bio Inc. ( CABA ) went public on 2019-10-25
Other Cabaletta Bio Inc. ( CABA ) financial metrics:
FCF:-83.57
Unlevered Free Cash Flow:-57.67
EPS:-2.48
Operating Margin:-699.03
Gross Profit Margin:-9.80
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-70.31
Beta:2.43
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Cabaletta Bio Inc. ( CABA ) :
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.